Andrew Berchuck, MD, is one of the Co-Directors of the Woman's Cancer Program within the DCI. For the past 25 years Dr. Berchuck has been actively involved in caring for women with gynecologic cancers while also leading a nationally recognized program in translational ovarian cancer research. He is Director of the Duke Division of Gynecologic Oncology, which is involved in a wide range of clinical trials in ovarian cancer including cooperative trials of the Gynecologic Oncology Group. Dr. Berchuck also serves as Head of the Gynecologic Cancer Program in the DCI. He is one of the leaders of the North Carolina Ovarian Cancer Study that seeks to identify genetic polymorphisms that affect ovarian cancer susceptibility. He is also head of the Steering Committee of the Ovarian Cancer Association Consortium.
Kimberly Blackwell, MD, is the leader of the Breast Cancer Group and a Professor of Medicine, Division of Medical Oncology. Her expertise includes serving as the PI on over 50 Phase 1-3 therapeutic trials over the past decade, including two which have led to the approval of lapatinib and T-DM1 for the treatment of HER2+ metastatic breast cancer. Her translational work focuses on validating predictive markers for novel therapeutics including HER2 signaling, D-dimer, EPO receptor, and genetic profiling. She is a Susan G. Komen Research Scholar and has served a number of leadership roles with this program locally, nationally, and internationally. She has served as a mentor to many medical oncology fellows who have gone on to remain in academic breast cancer positions.
Donald McDonnell, PhD, Program Co-Director, is the Chairman of Pharmacology and Cancer Biology and the Glaxo-Wellcome Professor of Molecular Cancer Biology. He has published over 240 manuscripts on the role of nuclear receptors in the pathogenesis of cancers and in other endocrinopathies. He has either founded or been involved directly as a founder in three biopharmaceutical firms; an activity which highlights his interest and ability to perform actionable translational research. The primary focus of his work in the last ten years has been in the development of mechanism-based approaches to develop novel classes of androgen receptor and estrogen receptor modulators for use in the treatment and prevention of breast cancer.